Advertisement





Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2001; 38:344-351
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wyse, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wyse, D. G.

CLINICAL STUDY: ELECTROPHYSIOLOGY

Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): drug testing and as-treated analysis

D. George Wyse, MD, PhD, FACC*, Mario Talajic, MD, FACC{dagger}, Gail E. Hafley, MS{ddagger}, Alfred E. Buxton, MD, FACC§, L. Brent Mitchell, MD||, Teresa K. Kus, MD, PhD, FACC||, Douglas L. Packer, MD, FACC, William H. Kou, MD, FACC#, Robert Lemery, MD, FACC**, Peter Santucci, MD{dagger}{dagger}, Denise Grimes, RN{ddagger}{ddagger}, Kathleen Hickey, RN§§, Carolyn Stevens, RN, Steven N. Singh, MD, FACC|| for the MUSTT Investigators

* University of Calgary, Calgary, Alberta, Canada
{dagger} Montreal Heart Institute, Montreal, Quebec, Canada
{ddagger} Duke Clinical Research Institute, Durham, North Carolina, USA
§ Temple University Hospital School of Medicine, Philadelphia, Pennsylvania, USA
|| Sacre Coeur Hospital, Montreal, Quebec, Canada
Mayo Clinic Foundation, Rochester, Minnesota, USA
# Veteran’s Administration Medical Center, Ann Arbor, Michigan, USA
** Rhode Island Hospital, Providence, Rhode Island, USA
{dagger}{dagger} Rush-Presbyterian Hospital, Chicago, Illinois, USA
{ddagger}{ddagger} Thoracic and Cardiovascular Institute, Lansing, Michigan, USA
§§ Columbia University Medical Center, New York, New York, USA
|| Veteran’s Administration Medical Center, Washington, District of Columbia, USA

Manuscript received November 10, 2000; revised manuscript received March 22, 2001, accepted April 26, 2001.

Reprint requests and correspondence: Dr. D. George Wyse, Division of Cardiology, University of Calgary, G009, Health Sciences Center, 3350 Hospital Drive Northwest, Calgary, AB Canada T2N 4N1
dgwyse{at}ucalgary.ca

OBJECTIVES

Using data from the Multicenter UnSustained Tachycardia Trial (MUSTT), we examined the factors used to select antiarrhythmic drug therapy and their impact on outcomes.

BACKGROUND

The MUSTT examined the use of programmed ventricular stimulation (PVS) to guide antiarrhythmic therapy in patients with coronary arteriosclerosis, left ventricular dysfunction and asymptomatic, unsustained ventricular tachycardia (VT). Trial outcomes may reflect factors used to select antiarrhythmic drug therapy.

METHODS

We compared subgroups of patients with inducible sustained VT randomized to PVS-guided antiarrhythmic therapy (n = 351), in particular those receiving PVS-guided antiarrhythmic drug therapy (n = 142) versus no antiarrhythmic therapy (controls, n = 353).

RESULTS

"Effective" antiarrhythmic drug therapy (i.e., the term "effective" was used to denote therapy that resulted in noninducible VT or hemodynamically stable induced VT) was found for 142 of the 351 patients (43%), most often at the first or second PVS session (125/142, 88%). Mortality among the 142 patients did not differ from that among control patients. Of these 142 patients, the PVS end point was noninducibility in 91 patients and stable VT in 51 patients. Mortality did not differ between these two groups either, but arrhythmia was numerically more frequent in the PVS-induced stable VT group. Mortality was greatest in the few patients receiving propafenone (unadjusted p = 0.07, adjusted p = 0.14 vs. controls), but mortality with all agents did not differ from that of controls, even after adjustment.

CONCLUSIONS

Even when presenting the results as favorably as possible, we found no benefit with PVS-guided drug therapy in patients with clinical unsustained VT who had inducible sustained VT. These findings are unaltered by using different end points for PVS or considering the response to individual drugs.

Abbreviations and Acronyms
  ICD = implantable cardioverter defibrillator
  MUSTT = Multicenter UnSustained Tachycardia Trial
  PVS = programmed ventricular stimulation
  VT = ventricular tachycardia




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346.
[Full Text] [PDF]


Home page
EuropaceHome page
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 746 - 837.
[Full Text] [PDF]


Home page
Eur Heart JHome page
D. G Katritsis and A.J. Camm
Nonsustained ventricular tachycardia: where do we stand?
Eur. Heart J., July 1, 2004; 25(13): 1093 - 1099.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. Kirchhof, H. Degen, M. R. Franz, L. Eckardt, L. Fabritz, P. Milberg, S. Laer, J. Neumann, G. Breithardt, and W. Haverkamp
Amiodarone-Induced Postrepolarization Refractoriness Suppresses Induction of Ventricular Fibrillation
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 257 - 263.
[Abstract] [Full Text]


Home page
CirculationHome page
K. Soejima and W. G. Stevenson
Ventricular Tachycardia Associated With Myocardial Infarct Scar: A Spectrum of Therapies for a Single Patient
Circulation, July 9, 2002; 106(2): 176 - 179.
[Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Does Electrophysiology Testing Adequately Guide Management of Unsustained VT?
Journal Watch Cardiology, October 12, 2001; 2001(1012): 6 - 6.
[Full Text]


Home page
J Am Coll CardiolHome page
J. W. Mason
Mindfully mining MUSTT
J. Am. Coll. Cardiol., August 1, 2001; 38(2): 352 - 354.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement